

DORSET MEDICINES ADVISORY GROUP

Recommendation Summary



**Dorset
Clinical Commissioning Group**

The Dorset Medicines Advisory Group (DMAG) represents the four provider Trusts and GPs within the Clinical Commissioning Group (CCG). It provides recommendations to the CCG on the prescribing and commissioning of medicines.

Summary of recommendations considered at a meeting of the group on 12th November 2019. Formulary entries and associated documents can be accessed at www.dorsetformulary.nhs.uk.

| PRODUCT | DECISION | | COMMENTS |
|-----------------------------------|-------------------|----------------------|---|
| | Previous position | Recommended position | |
| 1. Products re-categorised | | | |
| Hepatitis B vaccine | Green | Red | for patients with renal disease in accordance with NHS England repatriation of responsibility back to renal units. |
| Mouthwash solution tablets | Green | Red | Has not been prescribed in primary care in the past 12 months |
| Pizotifen | Green | Amber | Highlighted in the NICE clinical guideline for recurrent migraine (NG150) as not being a clinically and cost-effective prophylactic treatment, therefore will only be used for new patients on the advice of a specialist |
| Retigabine | no entry | Non-formulary | To show it has been discontinued. |
| Strontium | Non-formulary | Amber | For a 6-12-month trial, for patients in whom no other treatment with other medicinal products approved for the treatment of osteoporosis is possible. |
| Azithromycin | Red | Amber SCG | For patients with COPD |
| Zafirlukast | Green | Non-formulary | To show it has been discontinued. |

| PRODUCT | DECISION | COMMENTS |
|--|---------------|---|
| 2. New requests | | |
| Semaglutide | Amber SCG | For any licensed indication, feedback in 12 months was requested. |
| Semglee® (biosimilar insulin glargine) | Green | First choice insulin glargine on the formulary |
| Liothyronine | Red | For treatment resistant depression, following updated RMOG guidance. |
| Mydrane® | Red | For use during cataract surgery |
| Fixapost® | Green | A cost-effective alternative to existing formulary entries, for glaucoma where a preservative free option is needed |
| Guanfacine | Amber SCG | In line with NICE Guideline NG87 (diagnosis and management of attention deficit hyperactivity disorder) |
| Cariprazine (Reagila®) | Non-formulary | For the treatment of schizophrenia in adult patients |
| Trevicta® | Red | This is a 3-monthly paliperidone injection with a cost and safety profile similar to the monthly product. A useful option for those patients who would prefer 3 monthly injections. |
| Rivaroxaban | Green | in coronary artery disease or peripheral artery disease In line with NICE TA607 |
| Xeomin® (botulinum neurotoxin type A) | Red | for treating chronic sialorrhoea caused by neurological conditions in adults in line with NICE TA605 |
| 3. Products considered by NICE | | |
| <p>NICE TA 607 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease</p> <p>NICE TA605 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea</p> | | |
| 4. Miscellaneous recommendations by DMAG | | |

| PRODUCT | DECISION | COMMENTS |
|--|----------|---|
| Statement to enable brand prescribing of biosimilars | | “Most cost-effective brand to be chosen (product should <u>be brand prescribed</u>) that may be dictated by national contract and/or local decision making. It is expected that biosimilars would be used first line where appropriate”. |
| 5. Further Assessment / Evidence Required | | |
| The guideline - Investigation and Treatment of Adult Vitamin B12 (Cobalamin) Deficiency in Primary Care | | More information regarding deficiencies associated with a vegan diet was required. |
| The proposal to re-categorise sub-lingual fentanyl tablets from Red to Amber SCG. | | more information being sought to understand the current position. |
| 6. New documents approved | | |
| Shared Care Guideline Azithromycin for long-term use in COPD or bronchiectasis. | | |
| 7. Documents Reviewed | | |
| <p>Commissioning Statement GLP-1- Reviewed and updated to include semaglutide.</p> <p>Shared Care Guideline GLP-1- Amended to reflect the risk of diabetic retinopathy with semaglutide.</p> <p>Shared Care Guideline liothyronine – Amended following an update by the Regional Medicines Optimisation Committee (RMOC).</p> <p>Shared Care Guideline Attention Deficit Hyperactivity Disorder in adults aged over 17 years and in children and adolescents aged 6-17 years. Reviewed and updated to include Guanfacine.</p> <p>Commissioning Statement Rivaroxaban for preventing atherothrombotic events in people with coronary artery disease or peripheral artery disease.</p> <p>Commissioning Statement for the use of Xeomin® (BOTULINUM NEUROTOXIN TYPE A) for treating chronic sialorrhoea.</p> | | |

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset